Skip to content

Depression: all studies

Page 583 of 1,034: studies 5,821 to 5,830 of 10,336, newest first. Back to the depression overview

Research

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Proceedings of the National Academy of Sciences April 14, 2025 Jeremy R Tuck, Lee E. Dunlap, Yara A Khatib et al. 32 citations

Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the...

DOI: 10.1073/pnas.2416106122 (opens in new tab) LSD Neuroplasticity Neuropsychiatric disease Nonhallucinogenic +9

The use of Focused-Attention Meditation Combined with Muscle Relaxation (MR Therapy) in the treatment of Recurrent Isolated Sleep Paralysis (RISP)- two case reports

Archives of Psychiatry and Psychotherapy April 13, 2025 Paulina Wróbel-knybel, Leszek Wołkowski, Hanna Karakuła-juchnowicz

Recurrent isolated sleep paralysis (RISP) belongs to the parasomnias of the REM sleep. Currently, there are few treatment options for this disorder. Pharmacotherapy is reserved only for the most severe cases of RISP. The first-line treatment is cognitive-behavioural therapy, the availability of which is limited. A new treatment option is meditation-relaxation therapy (MR therapy), the...

DOI: 10.12740/app/191453 (opens in new tab) Meditation Sleep paralysis Relaxation psychology Psychotherapist +5

Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness.

Communications Psychology April 13, 2025 Martha N. Havenith, Max Leidenberger, Jelena Brasanac et al. 14 citations

Abstract Altered states of consciousness (ASCs), induced e.g. during psychedelic-assisted therapy, show potential to treat prevalent mental health disorders like depression and posttraumatic stress disorder. However, access to such treatments is restricted by legal, medical, and financial barriers. Circular breathwork may present a non-pharmacological and hence more accessible alternative to...

The Physical and Psychological Effects of Meditation

April 10, 2025 Pari Patel 14 citations

The Physical and Psychological Effects of MeditationPari Patel Meditation has many physical and psychological effects on the human body.Meditation originated from ancient Eastern culture and has been practiced for centuries.Meditation back then was considered a religious practice; however, it is not necessary to be religious to meditate.Trials conducted and respected research show that...

Somatic Meditation and the Embodied Mind: A Neuropsychological Review

April 10, 2025 Debajyoti Ray preprint

This review examines the neuropsychological basis of somatic meditation, exploring its relationship with embodied cognition theories and its therapeutic potential. Somatic meditation, which cultivates focused attention on internal bodily sensations (interoception), is increasingly recognized for addressing the embodied aspects of stress, trauma, and chronic pain. Drawing on insights linking...

DOI: 10.31219/osf.io/2qt3c_v1 (opens in new tab) Meditation Embodied cognition Neuropsychology Cognitive psychology +5

Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine.

ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo

Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for depression, PTSD, and addiction. Relaxing neural filters reveal altered states of consciousness, challenging perceptions of reality. This Viewpoint explores their neurobiological mechanisms and AI's role in augmenting psychiatric treatments.

Peak Experiences Matter

Journal of Humanistic Psychology April 9, 2025 Danielle Leonard, Thomas R. Brooks 1 citation

Peak and mystical experiences can be seen as states of consciousness that exist on a spectrum of varying intensity and duration. They are often described as moments of profound joy, ecstasy, and awe that involve feelings of noetic quality, decreased self-salience, and heightened interconnectedness. The renewed interest in psychedelics as a potential tool for therapeutic intervention has been...

In Vitro Psilocybin Synthesis by Co‐Immobilized Enzymes

Chemistry - A European Journal April 9, 2025 Tim Schäfer, Thomas Krüger, Jakob Worbs et al. 2 citations

Abstract Advanced clinical trials investigate the Psilocybe magic mushroom natural product psilocybin as a treatment against major depressive disorder. Currently, synthetic material is used to meet the demand for legitimate pharmaceutical purposes. Here, we report an in vitro approach to biocatalytically produce psilocybin on a solid‐phase matrix charged with five covalently bound biosynthetic...

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.

Neuropsychopharmacology April 9, 2025 Ellen Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold et al. 23 citations

Mood dysfunction is highly prevalent in Parkinson's disease (PD), a main predictor of functional decline, and difficult to treat-novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot...

DOI: 10.1038/s41386-025-02097-0 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Parkinson's disease treatment Psychedelic medicine Neurological research +1

A multi-institutional investigation of psilocybin’s effects on mouse behavior

bioRxiv (Cold Spring Harbor Laboratory) April 9, 2025 Odilia D Lu, Katrina White, Kendall Raymond et al. 18 citations preprint

ABSTRACT Studies reporting novel therapeutic effects of psychedelic drugs are rapidly emerging. However, the reproducibility and reliability of these findings could remain uncertain for years. Here, we implemented a multi-institutional collaborative approach to define the robust and replicable effects of the psychedelic drug psilocybin on mouse behavior. Five laboratories performed the same...

DOI: 10.1101/2025.04.08.647810 (opens in new tab) Full text (opens in new tab) Psychedelics Psilocybin research Behavioral studies Animal testing